CLINICAL TRIALS PROFILE FOR PREVYMIS
✉ Email this page to a colleague
All Clinical Trials for prevymis
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03728426 ↗ | Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection | Recruiting | Merck Sharp & Dohme Corp. | Phase 2 | 2019-01-11 | The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active cytomegalovirus infection or cytomegalovirus disease in patients with infections that are refractory or resistant to available treatments or who are experiencing organ dysfunction that makes unsafe the use of available antiviral treatments. |
| NCT03728426 ↗ | Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection | Recruiting | Amy C. Sherman, MD | Phase 2 | 2019-01-11 | The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active cytomegalovirus infection or cytomegalovirus disease in patients with infections that are refractory or resistant to available treatments or who are experiencing organ dysfunction that makes unsafe the use of available antiviral treatments. |
| NCT03728426 ↗ | Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection | Recruiting | Dana-Farber Cancer Institute | Phase 2 | 2019-01-11 | The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active cytomegalovirus infection or cytomegalovirus disease in patients with infections that are refractory or resistant to available treatments or who are experiencing organ dysfunction that makes unsafe the use of available antiviral treatments. |
| NCT04060277 ↗ | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation | Recruiting | National Cancer Institute (NCI) | Phase 2 | 2019-10-07 | This phase II trial studies how well Triplex vaccine works in preventing cytomegalovirus (CMV) infection in patients undergoing a hematopoietic stem cell transplantation. CMV is a virus that may be carried for life and does not cause illness in most healthy individuals. However, in people whose immune systems are lowered (such as those undergoing stem cell transplantation), CMV can reproduce and cause disease and even death. The Triplex vaccine is made up of 3 small pieces of CMV deoxyribonucleic acid (DNA) (the chemical form of genes) placed into a weakened virus called modified vaccinia Ankara (MVA) that may help produce immunity (the ability to recognize and respond to an infection) and reduce the risk of developing complications related to CMV infection. |
| NCT04060277 ↗ | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation | Recruiting | City of Hope Medical Center | Phase 2 | 2019-10-07 | This phase II trial studies how well Triplex vaccine works in preventing cytomegalovirus (CMV) infection in patients undergoing a hematopoietic stem cell transplantation. CMV is a virus that may be carried for life and does not cause illness in most healthy individuals. However, in people whose immune systems are lowered (such as those undergoing stem cell transplantation), CMV can reproduce and cause disease and even death. The Triplex vaccine is made up of 3 small pieces of CMV deoxyribonucleic acid (DNA) (the chemical form of genes) placed into a weakened virus called modified vaccinia Ankara (MVA) that may help produce immunity (the ability to recognize and respond to an infection) and reduce the risk of developing complications related to CMV infection. |
| NCT04312841 ↗ | Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab | Recruiting | Merck Sharp & Dohme Corp. | Phase 2 | 2020-09-15 | This phase II trial studies how well letermovir works for the prevention of cytomegalovirus reactivation in patients with hematological malignancies treated with alemtuzumab. Patients receiving treatment with alemtuzumab may experience cytomegalovirus reactivation. Letermovir may block cytomegalovirus replication and prevent infection. |
| NCT04312841 ↗ | Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab | Recruiting | National Cancer Institute (NCI) | Phase 2 | 2020-09-15 | This phase II trial studies how well letermovir works for the prevention of cytomegalovirus reactivation in patients with hematological malignancies treated with alemtuzumab. Patients receiving treatment with alemtuzumab may experience cytomegalovirus reactivation. Letermovir may block cytomegalovirus replication and prevent infection. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for prevymis
Condition Name
Clinical Trial Locations for prevymis
Trials by Country
Clinical Trial Progress for prevymis
Clinical Trial Phase
Clinical Trial Sponsors for prevymis
Sponsor Name
